Clinical activity, toxicity, biomarkers, and future development of CTLA-4 checkpoint antagonists Journal Article
| Authors: | Callahan, M. K.; Wolchok, J. D. |
| Article Title: | Clinical activity, toxicity, biomarkers, and future development of CTLA-4 checkpoint antagonists |
| Abstract: | Evidence that immune system can recognize, and in some cases control or even eliminate tumors, is increasingly clear. Encouraging T-cell activation by blocking regulatory or "checkpoint" molecules is a potent way to amplify anti-tumor immune responses. Successfully exploiting this concept, a new class of anti-cancer rapies, "checkpoint-blocking" antibodies has emerged. first checkpoint-blocking antibody to enter clinic was ipilimumab, an antibody that blocks co-inhibitory receptor cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4). Herein we review clinical development of CTLA-4 blocking antibodies, including preclinical studies, clinical activity, toxicities, search for potential biomarkers, and early clinical experience with combinations. © 2015 Elsevier Inc. |
| Keywords: | cancer survival; treatment outcome; treatment response; hepatitis; bevacizumab; sunitinib; advanced cancer; diarrhea; treatment duration; paclitaxel; cancer adjuvant therapy; comparative study; carboplatin; cytotoxic t lymphocyte antigen 4 antibody; dacarbazine; ipilimumab; ticilimumab; cancer immunotherapy; melanoma; neuropathy; antineoplastic activity; tumor marker; exemestane; prostate cancer; systematic review; pancreatitis; brain disease; colitis; maximum tolerated dose; hypothyroidism; uveitis; myopathy; phase 2 clinical trial (topic); phase 3 clinical trial (topic); budesonide; phase 1 clinical trial (topic); hypophysitis; conjunctivitis; thyroiditis; nephritis; vemurafenib; dabrafenib; trametinib; nivolumab; human; priority journal; article |
| Journal Title: | Seminars in Oncology |
| Volume: | 42 |
| Issue: | 4 |
| ISSN: | 0093-7754 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2015-08-01 |
| Start Page: | 573 |
| End Page: | 586 |
| Language: | English |
| DOI: | 10.1053/j.seminoncol.2015.05.008 |
| PROVIDER: | scopus |
| PUBMED: | 26320062 |
| DOI/URL: | |
| Notes: | Export Date: 2 October 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work